StockNews.AI
RXST
StockNews.AI
39 days

Johnson Fistel Begins Investigation on Behalf of RxSight, Inc. (RXST) Shareholders

1. Johnson Fistel investigates RxSight for potential securities law violations. 2. RxSight reported Q2 sales and revenue declines, revising guidance downwards by $42.5M. 3. Concerns arise over misleading statements about business outlook and product adoption.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The investigation and revenue drop indicate serious trust issues, reminiscent of past fraud cases affecting stock value significantly.

How important is it?

The investigation involves potential legal ramifications that typically lead to significant stock volatility.

Why Short Term?

The current investigation and financial adjustments can quickly sway investor sentiment and stock performance.

Related Companies

IARTALGNCERN
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether RxSight, Inc. (NASDAQ: RXST), or any of its executive officers, violated federal securities laws by making false or misleading statements or failing to disclose material information to investors. What if I purchased RXST securities?If you purchased RxSight securities and suffered losses on your investment, you may be eligible to participate in our investigation. To join, please click here: https://www.johnsonfistel.com/investigations/rxsight-inc Or for more information, contact Jim Baker at jimb@johnsonfistel.com or call (619) 814-4471. There is no cost or obligation to you. What is this about?The investigation focuses on whether RxSight misled investors regarding its business outlook and product adoption trends. On July 9, 2025, the company released preliminary financial results for the second quarter of 2025, reporting notable declines in Light Delivery Device (LDD) sales, usage of its light adjustable intraocular lenses (LALs), and total revenue. RxSight also revised its full-year 2025 guidance downward by roughly $42.5 million at the midpoint, citing “[a]doption challenges over the last few quarters” as a key factor behind the slowdown in LDD performance. What if I have relevant nonpublic information?Individuals with nonpublic information regarding RxSight should consider assisting with our investigation or exploring options under the SEC Whistleblower Program. Whistleblowers who submit original information to the SEC may, under certain conditions, receive rewards of up to 30% of any successful enforcement action. For more information, contact Jim Baker at (619) 814-4471 or jimb@johnsonfistel.com. About Johnson Fistel, PLLP | Top Law Firm for Securities Fraud & Investor RightsJohnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents both individual and institutional investors in shareholder derivative and securities class action lawsuits. We also serve international investors who have purchased securities on U.S. exchanges. Stay informed on significant stock drops and learn how Johnson Fistel can help you recover your losses. To learn more about our firm and attorneys, please visit www.johnsonfistel.com. Recent Achievements:In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, recognizing the firm’s leadership in securing approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel. This marks the eighth time the firm has earned this distinction based on the total dollar value of final recoveries. Attorney advertising.Past results do not guarantee future outcomes.Services may be performed by attorneys in any of our offices.Johnson Fistel, PLLP has paid for the dissemination of this promotional communication. Frank J. Johnson is the attorney responsible for its content. Contact:Johnson Fistel, PLLP501 W. Broadway, Suite 800, San Diego, CA 92101James Baker, Investor Relations or Frank J. Johnson, Esq.(619) 814-4471 | jimb@johnsonfistel.com | fjohnson@johnsonfistel.com 

Related News